Category: Kidney Cancer
The Effect of Interleukin 1 Beta Blockade on the Tumor Microenvironment
Based on a presentation by Charles G. Drake, MD, PhD, at the International Kidney Cancer Symposium 2020, November 6-7, Virtual Preclinical data suggest that interleukin […]
Highlights in Kidney Cancer
From the American Society of Clinical Oncology Genitourinary Cancers Symposium February 13-15, 2020 • San Francisco, California Phase 1/2 Trial of MK-6482 Demonstrates Activity Against […]
Highlights in Kidney Cancer
From the Eighteenth International Kidney Cancer Symposium November 15-16, 2019 • Miami, Florida Lenvatinib Plus Pembrolizumab Shrinks Metastatic Kidney Cancer After Previous Checkpoint Inhibitor A […]
Perioperative Approaches to Kidney Cancer
Abstract: This article provides an overview of the perioperative treatment strategies available for renal cancer. A review of the literature via PubMed, ClinicalTrials.gov, the American […]
Highlights in Kidney Cancer
From the American Society of Clinical Oncology Genitourinary Cancers Symposium February 14-16, 2019 • San Francisco, California Nivolumab Plus Ipilimumab Continues to Improve Survival in Renal […]
Contemporary Management of Advanced Renal Cell Carcinoma
Abstract: Kidney cancer is the eighth most commonly diagnosed cancer in the United States, and nearly one-third of patients have locally advanced or metastatic disease […]
Highlights in Kidney Cancer From the American Society of Clinical Oncology Genitourinary Cancers Symposium
Highlights in Kidney Cancer From the American Society of Clinical Oncology Genitourinary Cancers Symposium February 8-10, 2018 • San Francisco, California Atezolizumab Plus Bevacizumab Improves Progression-Free Survival […]
Cost-Effectiveness in the Surgical Care of Renal Cell Carcinoma
From the 16th International Kidney Cancer Symposium November 3-4, 2017, Miami, Florida When it comes to the surgical care of patients with kidney cancer, more is […]
How We Treat Brain Metastases in Metastatic Renal Cell Carcinoma
Overview • Brain metastasis in patients with metastatic renal cell carcinoma generally signifies a poor prognosis. • Surgical resection is an option for patients with […]
Current and Emerging First-Line Systemic Therapies in Clear Cell Renal Cell Carcinoma
H&O Which patients with clear cell renal cell carcinoma (RCC) are candidates for systemic therapy? BR All patients with clear cell RCC are potential candidates […]
Cabozantinib Approved for First-Line Treatment of Advanced Renal Cell Carcinoma
Cabozantinib (Cabometyx, Exelixis) received an expanded indication from the US Food and Drug Administration (FDA) on December 19 as a first-line treatment in patients with advanced […]
Highlights in Kidney Cancer From the 2017 American Society of Clinical Oncology Annual Meeting
1From the 2017 American Society of Clinical Oncology Annual Meeting June 2-6, 2017 • Chicago, Illinois Adjuvant Pazopanib Does Not Extend Disease-Free Survival in Locally Advanced […]
Highlights in Kidney Cancer
Highlights in Kidney Cancer: From the American Society of Clinical Oncology Genitourinary Cancers Symposium February 16-18, 2017 • Orlando, Florida Computer Assistance Reduces Errors in Evaluation […]
Combined Blockade of Vascular Endothelial Growth Factor and Programmed Death 1 Pathways in Advanced Kidney Cancer
Abstract: Targeted and immune-based therapies have improved outcomes in advanced kidney cancer, yet novel strategies are needed to extend the duration of these benefits and […]
Non–Clear Cell Renal Cell Carcinomas: Biological Insights and Therapeutic Challenges and Opportunities
Abstract: The non–clear cell renal cell carcinomas (nccRCCs) are a diverse group of rare-variant renal carcinomas. Each subtype harbors a distinct cell of origin and […]
Genetic Conditions Associated With a Predisposition to Kidney Cancer
Based on a presentation by W. Marston Linehan, MD, at the ASCO Genitourinary Cancers Symposium Scientists have identified at least 13 genes that predispose patients […]
The Future of Immunotherapy as Perioperative Therapy in Renal Cell Carcinoma
Reports from the International Kidney Cancer Symposium November 5-6, 2016, Miami, Florida Researchers are launching 2 new studies of checkpoint inhibitors as perioperative treatment for patients with […]
VEGF Inhibitors in Renal Cell Carcinoma
Abstract: The arrival of targeted therapies—vascular endothelial growth factor (VEGF) pathway inhibitors and mammalian target of rapamycin (mTOR) inhibitors—and programmed death 1 (PD-1) inhibitors has […]
Kidney Cancer News
Cancer Vaccine Fails to Improve Survival in Metastatic Renal Cell Carcinoma The addition of the IMA901 multipeptide cancer vaccine to sunitinib (Sutent, Pfizer) did not […]
Adjuvant Treatment for Renal Cell Carcinoma: Do We Finally Have a Major Breakthrough?
Clinical Advances in Hematology & Oncology Volume 14, Issue 11, November 2016 Devin N. Patel, MD, Robert A. Figlin, MD, and Hyung L. Kim, MD The […]